The Imperative for Comparative Studies in Nuclear Medicine: Elevating 177Lu-PSMA-617 in the Treatment Paradigm for mCRPC

J Nucl Med. 2024 Feb 1;65(2):224-225. doi: 10.2967/jnumed.123.266952.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Dipeptides / therapeutic use
  • Heterocyclic Compounds, 1-Ring / therapeutic use
  • Humans
  • Lutetium / therapeutic use
  • Male
  • Nuclear Medicine*
  • Prostate-Specific Antigen
  • Prostatic Neoplasms, Castration-Resistant* / diagnostic imaging
  • Prostatic Neoplasms, Castration-Resistant* / radiotherapy
  • Radiopharmaceuticals / therapeutic use
  • Retrospective Studies
  • Treatment Outcome

Substances

  • PSMA-617
  • Radiopharmaceuticals
  • Dipeptides
  • Heterocyclic Compounds, 1-Ring
  • Prostate-Specific Antigen
  • Lutetium